{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(11)"],"submitter":["Gal J"],"pubmed_abstract":["The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and allow for a more personalized use of this antiangiogenic agent. To that end, we aimed to establish risk scores for survival prognosis dichotomization based on classic clinico-pathological criteria combined or not with single nucleotide polymorphisms (SNPs). The genomic DNA of 306 patients was extracted and a panel of 13 SNPs, covering seven genes previously documented to be potentially involved in drug response, were analyzed by means of high-throughput genotyping. In receiver operating characteri"],"journal":["Pharmaceuticals (Basel, Switzerland)"],"pagination":["E414"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7700430"],"repository":["biostudies-literature"],"pubmed_title":["VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric Study."],"pmcid":["PMC7700430"],"pubmed_authors":["Desmoulins I","Merlano MC","Cottu PH","Milano G","Tredan O","Etienne-Grimaldi MC","Gal J","Goncalves A","Ebran N","Brest P","Chamorey E","Ferrero JM","Llorca L","Debled M","Brain E","Gilhodes J","Romieu G","Lemonnier J","Pierga JY","Dubot C"],"additional_accession":[]},"is_claimable":false,"name":"VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric Study.","description":"The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and allow for a more personalized use of this antiangiogenic agent. To that end, we aimed to establish risk scores for survival prognosis dichotomization based on classic clinico-pathological criteria combined or not with single nucleotide polymorphisms (SNPs). The genomic DNA of 306 patients was extracted and a panel of 13 SNPs, covering seven genes previously documented to be potentially involved in drug response, were analyzed by means of high-throughput genotyping. In receiver operating characteri","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2026-04-07T17:19:06.662Z","creation":"2021-02-20T03:03:57Z"},"accession":"S-EPMC7700430","cross_references":{"pubmed":["33238394"],"doi":["10.3390/ph13110414"]}}